Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 August 2021 | Story Nonsindiso Qwabe | Photo Sonia Small (Kaleidoscope Studios)
New member of the Pontifical Academy of Social Sciences - Prof Pearl Sithole

Social scientist and Vice-Principal: Academic and Research on the Qwaqwa Campus, Prof Pearl Sithole, was appointed by Pope Francis as a member of the Pontifical Academy of Social Sciences for her stellar work in social sciences. 
Academicians are appointed by the Pope on the basis of their competencies in the social sciences and their moral integrity.

Prof Sithole said she was looking forward to sharing meaning and impact with the world through a space dedicated to the social sciences. “It’s a great honour. I’m feeling really humbled. The social sciences and humanities are a hugely necessary space to make meaning of the world, but for some reason, in the pecking order, they were relegated to a space that is thought of last. This appointment is to a dedicated space – to say, let’s look at issues through that lens.”
The Pontifical Academy of Social Sciences was established by Pope John Paul II in 1994 with the aim of promoting the study and progress of the social sciences, primarily economics, sociology, law, and political science. To achieve its aims, the academy organises conferences and workshops on specific themes, promotes scientific surveys and research, and publishes publications. 

Prof Sithole said the academy provides a wonderful way of reminding academicians of the importance of relating science to the real world. 

“What I like about it is that it demystifies science. It says, be excellent in your field but be able to converse for impact, be able to come to a forum that worries about specific issues, it still encourages publications and pure science/scientific endeavours, advancements in their field, but sometimes people come together to look at an issue from various angles. For me, it’s such a wonderful way of saying we must remember that we are doing science in order to relate to the world, not just to understand for the sake of understanding,” she said.

Make a genuine effort to make a difference in whatever you do, and your work will speak for itself.- Prof Pearl Sithole. 

The appointment also coincides with Women’s Month, and Prof Sithole said she takes great pride in her womanhood. 

“I am a mother and a daughter. I strive to pinpoint problems and offer solutions. I am a social scientist. I’ve made it a mission to study how systems affect people by infusing humanity within the systems. Women have been made to be apologetic about the qualities that define us as women, which we bring especially into leadership. I don’t apologise for my emotions. I don’t apologise for my multitasking abilities; however, I do feel that women are often abused for having these.”

What would you say makes you a UFS woman of quality, impact, and care?

I am the sort of person who strongly believes that your work should speak for itself. I don’t work for accolades. My approach to life is to work genuinely to make a difference, and your work will speak for itself. If you wake up every day to genuinely make a difference, it is enough. You get a lot of satisfaction in life, and you sleep better because you know you have given it your best, and you know that sometimes you can actually see it making a difference.

What advice would you give to the 15-year-old you?

I would say, be true to yourself. At a younger age, you want to chase all sorts of aspirations that look glamorous, which is not a bad thing, because you have to have appetite; but in your appetite for excellence and as someone who lives for a purpose, be true to yourself. Be able to design a life that aspires, but at the same time be adaptable to what you discover your strengths to be.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept